The global Overactive Bladder (OAB) Therapeutics market was valued at US$ 3194.5 million in 2020 and is expected to reach US$ 3585.5 million by the end of 2027, growing at a CAGR of 1.6% during 2021-2027.
Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.
Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.
Global Overactive Bladder (OAB) Therapeutics Market: Drivers and Restrains
The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.
A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.
Global Overactive Bladder (OAB) Therapeutics Market: Segment Analysis
The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.
Key Companies profiled in this report are Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.
Segment by Type
- Anticholinergic Agents
- Beta-3 Adrenoreceptor Agonists
Segment by Application
Table of Content:
1 Overactive Bladder (OAB) Therapeutics Market Overview
2 Overactive Bladder (OAB) Therapeutics Market Competition by Manufacturers
3 Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario by Region
4 Global Overactive Bladder (OAB) Therapeutics Historic Market Analysis by Type
5 Global Overactive Bladder (OAB) Therapeutics Historic Market Analysis by Application
6 Key Companies Profiled
7 Overactive Bladder (OAB) Therapeutics Manufacturing Cost Analysis
8 Marketing Channel, Distributors and Customers
9 Overactive Bladder (OAB) Therapeutics Market Dynamics
10 Global Overactive Bladder (OAB) Therapeutics Market Forecast
11 Research Finding and Conclusion
12 Methodology and Data Source
Company Name: The Market Reports
Contact Person: Shirish Gupta